DDInter1662 DDInter286
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Sertraline {u} (Compound) binds {v} (Gene) SLC6A4
SLC6A4 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Sertraline {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Sertraline {u} (Compound) resembles {v} (Compound) Maprotiline
Maprotiline {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Sertraline {u} (Compound) resembles {v} (Compound) Maprotiline
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Sertraline {u} (Compound) resembles {v} (Compound) Maprotiline
Maprotiline {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Sertraline {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Sertraline {u} (Compound) resembles {v} (Compound) Maprotiline
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Sertraline {u} (Compound) resembles {v} (Compound) Maprotiline
Maprotiline {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Sertraline {u} (Compound) resembles {v} (Compound) Maprotiline
Maprotiline {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Sertraline {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Salivary hypersecretion {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Sertraline (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Sertraline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Sertraline (Compound) resembles Maprotiline (Compound) and Maprotiline may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Sertraline (Compound) resembles Maprotiline (Compound) and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Sertraline (Compound) resembles Maprotiline (Compound) and Maprotiline may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Sertraline (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Sertraline (Compound) resembles Maprotiline (Compound) and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Caplacizumab
Sertraline (Compound) resembles Maprotiline (Compound) and Maprotiline may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Caplacizumab
Sertraline (Compound) resembles Maprotiline (Compound) and Maprotiline may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Caplacizumab
Sertraline (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab